Abstract Library

#2886 Risk Factors for Short Recurrence-Free Survivals after Resection of PanNET Liver Metastasis: Single Institutional Analysis

Introduction: Although the treatment of PanNEN has improved survivals with development of pharmacotherapy recently, surgery is the first choice if curative resection is expected to be achieved. However, most of the patients undergo recurrence after resection of the liver metastasis even after curative resection. Therefore, it is important to identify who gains longer RFS by resection.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Masui T, Anazawa T, Nagai K, Sato A, Nakano K,

Keywords: liver metastasis, PanNEN, resection, indication,

#2776 The Effects of Somatostatin Analogues on HbA1c and BMI in the Treatment of Neuroendocrine Tumours

Introduction: Long acting somatostatin analogues (SSA) are the most commonly used drugs in the management of neuroendocrine tumours (NETs) due to their ability to control symptoms and prolong survival. SSAs use is associated with changes in glucose metabolism. However, there is lack of data for such effects in patients with NETs. We evaluated the effects of SSA on BMI and HbA1c in our cohort of patients with NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Patel K

Authors: Patel K, Nahar A, Elhassan Y, Shah T, Ayuk J,

Keywords: Somatostatin analogues, Diabetes, Neuroendocrine tumour, HbA1c, BMI,

#2167 Evaluation of Streptozocin-Based Chemotherapeutic Regimens for Advanced Pancreatic Neuroendocrine Tumors: A Multi-Center Clinical Study in Japan

Introduction: Streptozocin (STZ) has been used as a key drug against advanced pancreatic neuroendocrine tumors (pNETs). The standard in many countries is a daily STZ regimen combined with 5-fluorouracil administered once daily for 5 days every 6 weeks. However, in Japan, STZ was only covered by insurance beginning in 2015, and STZ is often used as monotherapy, as either a daily or a weekly regimen. There are few reports on STZ monotherapy for pNETs.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author:

Authors: Sakamoto Y, Hijioka S, Shibuya H, Ito T, Imamura M,

Keywords: Streptozocin, pNETs,

#1688 Pancreatic NET-G3 Does Not Respond to Platinum-Based Chemotherapy: A Multicenter Study of Neuroendocrine Carcinomas

Introduction: Recent studies　have shown that Pancreatic neuroendocrine carcinomas (NECs) contain well-differentiated NETs with high proliferative activity (WDNET-G3), as well as poorly differentiated NECs (PDNECs). Although patients with pNEC show variable responses to platinum-based chemotherapy, predictors of the response are unknown.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Hijioka S

Authors: Hijioka S, Hosoda W, Matsuo k, Ueno M, Furukawa M,

Keywords: NET G3, NEC, KRAS, Rb,

#1657 Establishment of Japan NeuroEndocrine Tumor Society and Its Registration System

Introduction: In 2012, many nation-wide gastroenterologists, endocrinologists, surgeons, radiologists and pathologists have established Japan NeuroEndocrine Tumor Society (JNETS) in Japan. JNETS is now composed of 304 institutes.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Masui T

Authors: Masui T, Imamura M, Ito T, Unno M, Okusaka T,

Keywords: registry system, Japan,,